Novel Bio

Coming – September 02

A Better Way To DNA

Date and Time

September 02

–

4:00 PM ET 1:00 PM PT

Details will be provided upon RSVP approval

About this Event

Novel Bio is an innovator that’s poised to disrupt the plasmid DNA manufacturing industry.

The company is living up to its name by replacing 50-year-old DNA production technology with their proven and proprietary NBx Platform. It drastically improves speed, yield, cost, and quality in DNA manufacturing.

Novel Bio has multiple revenue streams: As a CDMO they are delivering DNA on demand for more than 10 clients with a 100% retention rate. They also sell their NBx CyClone Cell Line to over 25 clients including leading healthcare organizations including the NIH, Regeneron, AstraZeneca and others. NBx Cyclone offers a drop-in replacement for the current workflows, delivering up to 10x more plasmids with superior DNA quality. Best of all, it doesn’t require new equipment or retraining for lab staff.

Register today to join our Fireside Chat with Novel Bio co-founder and CEO, Pankaj Khanna, to hear about the company’s plans to expand manufacturing and grow their business development team. With a backlog of customers and revenue constrained by capacity, Novel Bio is ready to scale quickly, and using conservative revenue estimates, It is projecting break-even by the end of 2026.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.